

09-14-04

IFW

DOCKET NO.: ISIS-5207

PATENT



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of:

Brenda F. Baker, et al.

Confirmation No.: 5280

Application No.: 10/701,236

Group Art Unit: 1616

Filing Date: November 4, 2003

Examiner: Not Yet Assigned

**For: SUGAR SURROGATE-CONTAINING OLIGOMERIC COMPOUNDS AND
COMPOSITIONS FOR USE IN GENE MODULATION**

EXPRESS MAIL LABEL NO: EL999288050US

DATE OF DEPOSIT: September 13, 2004

EL999288050US

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 CFR § 1.56 and in accordance with 37 CFR §§ 1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 CFR § 1.56(b).

- ☒ In accordance with § 1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified application, within three months of the date of entry into the national stage of the above identified application as set forth in § 1.491, before the mailing date of a first Office Action on the merits of the above-identified application, or

before the mailing date of a first Office Action after the filing of request for continued examination under § 1.114, no additional fee is required.

- ☐ In accordance with § 1.97(c), this Information Disclosure Statement is being filed after the period set forth in § 1.97(b) above but before the mailing date of either a Final Action under § 1.116 or a Notice of Allowance under § 1.311, or before an action that otherwise closes prosecution in the application, therefore:

- ☐ Certification in Accordance with § 1.97(e) is attached; or
- ☐ The fee of \$180.00 as set forth in § 1.17(p) is attached.

- ☐ In accordance with § 1.97(d), this Information Disclosure Statement is being filed after the mailing date of either a Final Action under § 1.113 or a Notice of Allowance under § 1.311 but before, or simultaneously with, the payment of the Issue Fee, therefore included are: Certification in Accordance with § 1.97(e); and the submission fee of \$180.00 as set forth in § 1.17(p).

- ☒ Copies of reference numbers 212-219 listed on the attached Form PTO-1449 are enclosed herewith.

- ☒ A copy of reference number 220 on the attached Form PTO 1449 is not required to be submitted pursuant to 37 CFR § 1.98(a)(2)(i).

- ☐ Copies of references - are not being submitted because they were previously cited by or submitted to the U.S. Patent and Trademark Office in patent application number , filed for which a claim for priority under 35 U.S.C. § 120 has been made in the instant application.


- ☐ The relevance of those listed references which are not in the English language is as follows:

Enclosed is a copy of the PCT International Search Report dated August 23, 2004 (number 212 on Form PTO-1449), which indicates the references considered to be relevant.

There are no listed references which are not in the English language.


Please charge any deficiency or credit any overpayment to Deposit Account No. 23-3050. This form is submitted in duplicate.

Date: September 13, 2004



John A. Harrelson, Jr.
Registration No. 42,637

WOODCOCK WASHBURN LLP
One Liberty Place - 46th Floor
Philadelphia, PA 19103
Telephone: (215) 568-3100
Facsimile: (215) 568-3439



Form PTO-1449 Modified List of Patent and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office		Docket No. ISIS-5207	Application No. 10/701,236
		Applicant Brenda F. Baker, et al.	
		Filing Date November 4, 2003	Group 1616
		Confirmation No. 5280	
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
	212	Copy of the PCT International Search Report dated August 23, 2004 (PCT/US03/35063)	
	213	Beigelman, L., et al., "Chemical modification of hammerhead ribozymes," <i>J. of Biological Chem.</i> , 1995 , 270(43), 257082-25708	
	214	Caplen, N.J., et al., "Specific inhibition of gene expression by small double-stranded RNAs in invertebrate and vertebrate systems," <i>PNAS</i> , 2001 , 98(17), 9742-9747	
	215	Czauderna, F., et al., "Structural variations and stabilizing modifications of synthetic siRNAs in mammalian cells," <i>Nucleic Acids Res.</i> , 2003 , 31(11), 2705-2716	
	216	Elbashir S.M., "Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells," <i>Nature</i> , 2001 , 411, 494-498	
	217	Paddison, P.J., et al., "Stable suppression of gene expression by RNAi in mammalian cells," <i>PNAS</i> , 2002 , 99(3), 1443-1448	
	218	Sui, G., et al., "A DNA vector-based RNAi technology to suppress gene expression in mammalian cells," <i>PNAS</i> , 2002 , 99(8), 5515-5520	
	219	Yu, J.-Y., et al., "RNA interference by expression of short-interfering RNAs and hairpin RNAs in mammalian cells," <i>PNAS</i> , 2002 , 99(9), 6047-6052	
EXAMINER		DATE CONSIDERED	



Form PTO-1449 Modified List of Patent and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office	Docket No. ISIS-5207	Application No. 10/701,236
	Applicant Brenda F. Baker, et al.	
	Filing Date November 4, 2003	Group 1616
	Confirmation No. 5280	

U. S. PATENT DOCUMENTS

Examiner Initial		Document No.	Date	Name	Class	Subclass
	220	2003/0143732 A1	07/31/03	Fosnaugh, et al.	435	325

FOREIGN PATENT DOCUMENTS

Examiner Initial		Document No.	Date	Country	Translation	
					YES	NO

EXAMINER	DATE CONSIDERED
-----------------	------------------------